|
|
SFX by Ex Libris Inc.
|
List of services to meet your request
|
|||||||||
|
|||||||||
© 2024 SFX by Ex Libris Inc. | Cookie Policy
CrossRef Omogočeno
![](https://beacon01.alma.exlibrisgroup.com/boom/apache_pb.gif?SRVR=adz.izum.si&IP=193.2.126.232&A=SFX&P=SFXMenu&S=sBC969F06-5E26-11EF-AD32-29E284CE164B&I=39IZM&T=&OP=Display&O=html&O1=15608988&O2=3710000000479512&O3=&O4=summon.serialssolutions.com&O5=https%3A%2F%2Fadz.izum.si%2Fsfxlcl41%3Fctx_enc%3Dinfo%253Aofi%252Fenc%253AUTF-8%26ctx_ver%3DZ39.88-2004%26rfr_id%3Dinfo%253Asid%252Fsummon.serialssolutions.com%26rft.atitle%3DTargeting%2520myeloid%2520cells%2520for%2520cancer%2520immunotherapy%253A%2520Siglec-7%252F9%252F10%252F15%2520and%2520their%2520ligands%26rft.au%3DBoelaars%252C%2520Kelly%26rft.au%3Dvan%2520Kooyk%252C%2520Yvette%26rft.date%3D2024-03-01%26rft.epage%3D241%26rft.externalDocID%3DS2405803323002406%26rft.genre%3Darticle%26rft.issn%3D2405-8033%26rft.issue%3D3%26rft.jtitle%3DTrends%2520in%2520Cancer%26rft.pub%3DElsevier%2520Inc%26rft.spage%3D230%26rft.volume%3D10%26rft_id%3Dinfo%253Adoi%252F10.1016%252Fj.trecan.2023.11.009%26rft_val_fmt%3Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal&O6=1-ELSEVIER_SCIENCEDIRECT_AUTOLOAD_JOURNALS-getFullTxt-object,2-ELSEVIER_SCIENCEDIRECT_AUTOLOAD_JOURNALS_20221021_LCL-getFullTxt-object,3-UNPAYWALL-getFullTxt-object,4-DOI-getDOI-object,5-COBIB_SI_LCL-getHolding-object,6-ELSEVIER_SCOPUS_FIS_LCL-getAbstract-object,7-REFWORKS_EXPORT_TOOL-getReference-object,8-GOOGLE_SCHOLAR_FREE-getWebSearch-object,9-WWW_SEARCH_ENGINES_FREE-getWebSearch-object&O7=1.40209&O8=N&O9=<ctx:context-object identifier="urn:sfxstat:15608988-sBC969F06-5E26-11EF-AD32-29E284CE164B" timestamp="2024-08-19T14:29:54Z" xmlns:ctx="info:ofi/fmt:xml:xsd:ctx">
<ctx:referent>
<ctx:identifier>urn:sfxid:3710000000479512</ctx:identifier>
<ctx:metadata-by-val>
<ctx:format>info:ofi/fmt:xml:xsd:journal</ctx:format>
<ctx:metadata>
<jnl:journal xmlns:jnl="info:ofi/fmt:xml:xsd:journal">
<jnl:atitle>Targeting myeloid cells for cancer immunotherapy: Siglec-7/9/10/15 and their ligands</jnl:atitle>
<jnl:jtitle>Trends in Cancer</jnl:jtitle>
<jnl:date>2024-03-00</jnl:date>
<jnl:spage>230</jnl:spage>
<jnl:epage>241</jnl:epage>
<jnl:issn>2405-8033</jnl:issn>
<jnl:volume>10</jnl:volume>
<jnl:issue>3</jnl:issue>
<jnl:genre>article</jnl:genre>
<jnl:eissn>2405-8025</jnl:eissn>
<jnl:language>eng</jnl:language>
<jnl:authors></jnl:authors>
</jnl:journal>
</ctx:metadata>
</ctx:metadata-by-val>
</ctx:referent>
<ctx:requester>
<ctx:identifier>urn:ip:b26b6218931a5ac8e88cf8495fcddbba3d054aaf</ctx:identifier>
<ctx:identifier>urn:UUID:sBC969F06-5E26-11EF-AD32-29E284CE164B</ctx:identifier>
</ctx:requester>
<ctx:referrer>
<ctx:identifier>info:sid/summon.serialssolutions.com</ctx:identifier>
</ctx:referrer>
<ctx:service-type>
<ctx:metadata-by-val>
<ctx:format>info:ofi/fmt:xml:xsd:svcList</ctx:format>
<ctx:metadata>
<svc:svcList xmlns:svc="http://www.exlibrisgroup.com/schema/info:ofi/fmt:xml:xsd:sch_svc"></svc:svcList>
</ctx:metadata>
</ctx:metadata-by-val>
</ctx:service-type>
<ctx:resolver>
<ctx:identifier>https://adz.izum.si/sfxlcl41</ctx:identifier>
</ctx:resolver>
</ctx:context-object>
&)